



November 14, 2025

For Immediate Release

Company name: VITAL KSK HOLDINGS, INC.
 Representative: Taisuke Murai, President & CEO
 Company address: 1-1-12, Tsurumaki, Setagaya-ku, Tokyo
 (Securities Code: 3151, TSE Prime Market)
 Contact: Kenta Sato, Executive Officer,
 Manager of Corporate Planning Department
 (Tel. +81-3-5787-8565)

Notice Regarding Revision of Consolidated Financial Forecasts for Fiscal Year 2025

VITAL KSK HOLDINGS, INC. (hereinafter "the Company") hereby announces that at the Board of Directors meeting held on November 14, 2025, the Company has revised its consolidated financial forecasts for Fiscal Year 2025 (previously announced on May 14, 2025) as follows.

1. Revision of Consolidated Financial Forecasts for the Current Fiscal Year

(1) Revision of Consolidated Financial Forecasts for Fiscal Year 2025 (April 1, 2025 - March 31, 2026)

	Net Sales	Core Operating Profit	Operating Profit	Ordinary Profit	Profit Attributable to Owners of Parent	Basic earnings per share
Previous Forecast (A)	Million yen 620,000	Million yen 6,000	Million yen 5,100	Million yen 6,000	Million yen 7,200	Yen 149.15
Revised Forecast (B)	604,000	5,100	3,900	7,700	7,400	153.07
Change (B-A)	(16,000)	(900)	(1,200)	1,700	200	-
Percentage Change (%)	(2.6)	(15.0)	(23.5)	28.3	2.8	-
(Reference) Previous Year Results (Fiscal Year 2024)	600,370	-	5,706	6,970	7,308	149.02

(2) Reasons for the Revision

As announced today, in the consolidated financial results for the first half of the fiscal year, our Group's core pharmaceutical wholesale business has experienced decreased sales due to the impact of drug price revisions and competitive bidding in specific areas, and sufficient improvement is not expected in the second half.

Furthermore, regarding profitability, in addition to the impact of the aforementioned decrease in sales, research and development expenses related to the pharmaceutical business are expected to increase beyond initial estimates as clinical trial details are finalized, and operating income is expected to fall below the previous forecast.

On the other hand, as stated in the "Notice Regarding Recording of Non-Operating Income and Notice Regarding Recording of Gain on Sales of Investment Securities (Extraordinary Income) Partial Amendment to the Content" announced today, following the tender offer for shares of CareNet, Inc., the investment returns (non-operating income) from MIJ Healthcare No. 1 Investment Limited Partnership, in which the Group has invested, are expected to significantly exceed the previous forecast for ordinary income.

Based on these circumstances, we have revised the consolidated financial forecast for Fiscal Year 2025 that was announced on May 14, 2025. For details of the second quarter consolidated financial results, please refer to the "Consolidated Financial Statements for the Second Quarter of the Fiscal Year Ending March 31, 2026 [Japanese GAAP]" released today.

(Note) The above forecasts are based on information available as of the date of this announcement, and actual results may differ from these forecasted figures due to various factors.